Capstan Therapeutics announces $175M Oversubscribed Series B Financing

San Diego, CA, March 20, 2024 (Capstan) -- Capstan Therapeutics, Inc. (“Capstan”), has successfully secured a $175 million oversubscribed Series B financing to advance their groundbreaking work in in vivo cell reprogramming. Led by RA Capital Management, this funding round also saw participation from new investors such as Forbion, Johnson & Johnson Innovation – JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments.

Read full article here.